Psilocybin for major depressive disorder: a systematic review of randomized controlled studies.

ABSTRACT:

Objectives

The purpose of this systematic review of randomized controlled trials (RCTs) was to evaluate the effectiveness, safety, and tolerability of psilocybin in adult patients with major depressive disorder (MDD).

Methods

A systematic search (up to September 14, 2023) was conducted for RCTs that examined the efficacy, safety, and tolerability of psilocybin in physically healthy adult patients with MDD. Three independent researchers extracted data from publications where the primary outcome was a change in depressive symptoms, and key secondary outcomes were changes in anxiety symptoms and suicidal ideation, discontinuation rates for any reason, and adverse drug reactions (ADRs).

Results

Five RCTs with 472 adult patients with MDD on psilocybin (n = 274) and control

SUBMITTER: Li LJ 

PROVIDER: S-EPMC11456834 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature